Table 2.
Factors associated with septic shock after irinotecan-containing chemotherapy identified by univariable logistic regression analysis
| Possible risk factors | Septic shock [n = 3]a | Without septic shock [n = 144]b | OR (95% CI) |
|---|---|---|---|
| Age (years) | 70 (60–73) | 57.5 (13.2) | 1.06 (0.97–1.20) |
| BMI (kg/m2) | 18.3 (15.0–19.7) | 21.7 (4.4) | 0.74 (0.42–1.06) |
| Neutrophil count (/μL) | 4114 (4066–5105) | 3791 (1516) | 1.00 (0.9996–1.0009) |
| Hemoglobin (g/dL) | 12.6 (9.7–12.8) | 11.5 (1.9) | 1.09 (0.59–1.81) |
| Platelet count (×104/μL) | 26.2 (22.9–26.4) | 26.3 (8.0) | 0.99 (0.84–1.13) |
| Serum creatinine (mg/dL) | 0.71 (0.61–1.20) | 0.64 (0.18) | 31.2 (0.57–1022) |
| Total bilirubin (mg/dL) | 0.7 (0.6–0.9) | 0.6 (0.2) | 19.8 (0.28–661) |
| UGT1A1 polymorphismc | 3 (100%) | 53 (43.4%)d | 9.09 (0.86–1233)d |
| History of pelvic irradiation | 3 (100%) | 14 (9.7%) | 63.0 (5.71–8635) |
| Administration of hangeshashinto | 0 (0%) | 10 (6.9%) | 1.83 (0.01–20.8) |
| Platinum combination therapy | 3 (100%) | 135 (93.8%) | 0.49 (0.04–67.8) |
| History of chemotherapy | 3 (100%) | 57 (39.6%) | 10.7 (1.01–1442) |
| History of abdominal surgery | 1 (33.3%) | 61 (42.4%) | 0.81 (0.07–6.28) |
BMI body mass index, OR odds ratio, CI confidence interval, UGT1A1 uridine diphosphate glucuronosyltransferase 1A1
aData are expressed as median (range) or number (%)
bData are expressed as mean (standard deviation) or number (%)
cUGT1A1*6/*6, *28/*28, *6/*28, *1/*6, *1/*28
dThe results of UGT1A1 polymorphism were not available in 22 cases. The percentages and ORs shown were calculated excluding these cases (complete case analysis)